Benzinga | Jun 17, 2021 10:26AM EDT

Synlogic, Roche Ink Research Pact For Inflammatory Bowel Disease Therapy

* Synlogic Inc (NASDAQ:SYBX) has entered into a research collaboration agreement with Roche Holding AG (OTC:RHHBY) for the discovery of Synthetic Biotic medicine for inflammatory bowel disease (IBD).

* Under the terms of the agreement, Synlogic and Roche will collaborate to develop a Synthetic Biotic treatment addressing an undisclosed novel target in IBD.

* After the research period, Roche will have the exclusive option to enter a licensing and collaboration agreement to develop further and commercialize the program.

* Price Action: SYBX shares are up 2.2% at $4.19 during the premarket session on the last check Thursday.